References
- Abraham W, Gill A, Ahmed A, Sielczak M, Lauredo I, Botinnikova Y, Lin KC, Pepinsky B, Leone D, Lobb R, et al. A small molecule, tight binding inhibitor of the integrin α4β1 blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. American Journal of Respiratory and Critical Care Medicine 2000; 162: 603–611
- Anwar AR, Walsh GM, Cromwell O, Kay AB, Wardlaw AJ. Adhesion to fibronectin primes eosinophils via alpha 4 beta 1 (VLA-4). Immunology 1994; 82: 222–228
- Carlos T, Harlan J. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068–2101
- Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR. VCAM-1 on activated endothelium interacts with the leucocyte integrin VLA-4/fibronectin binding site. Cell 1990; 60: 577–584
- Ibarra-Rubio M, Pena J, Chaverri J. Kinetic and inhibitory characteristics of serum angiotensin-converting enzyme from nine mammalian species. Comparative Biochemistry and Physiology. Part B 1989; 92: 399–403
- Koo G, Shah K, Ding G, Xiao J, Wnek R, Doherty G, Tong X, Pepinsky R, Lin K-C, Hagmann W, et al. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. American Journal of Respiratory and Critical Care Medicine 2003; 167: 1400–1409
- Kudlacz E, Whitney C, Andresen C, Duplantier A, Beckius G, Chupak L, Klein A, Kraus K, Milici A. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule α4β1 antagonists. Journal of Pharmacology and Experimental Therapeutics 2002; 301: 747–762
- Lin K, Ateeq H, Hsuing S, Chong L, Zimmerman C, Castro A, Lee W, Hammond C, Kalkunte S, Chen L, et al. Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses. Journal of Medicinal Chemistry 1999; 42: 920–934
- Lobb RR, Hemler ME. The pathophysiologic role of α4 integrins in vivo. Journal of Clinical Investigation 1994; 94: 1722–1728
- Ng K, Vane J. Conversion of angiotensin I to angiotensin II. Nature 1967; 216: 762
- Ng K, Vane J. Fate of angiotensin I in the circulation. Nature 1968; 218: 144
- Omura T, Sato R. The carbon-monoxide binding pigment of liver microsomes. Journal of Biological Chemistry 1964; 239: 2370–2378
- Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyl S, Chi-Rosso G, Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203–1211
- Popper HH, Pailer S, Wurzinger G, Feldner H, Hesse C, Eber E. Expression of adhesion molecules in allergic lung diseases. Virchows Archiv 2002; 440: 172–180
- Ryan MJ, Sigmund CD. ACE, ACE inhibitors and other JNK. Circulation Research 2004; 94: 1–3
- Roth M, Weitzman A, Piquilloud Y. Converting enzyme content of different tissues of the rat. Experientia 1969; 25/12: 1247
- Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: An update. Clinical Pharmacokinetics 2002; 41: 207–224
- Weisser K, Schloos J. The role of enzyme and substrate concentration in the evaluation of serum angiotensin converting enzyme (ACE) inhibition by enalaprilat in vitro. Biochemical Pharmacology 1991; 42: 1729–1737
- White C. Pharmacologic, pharmacokinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588–599